MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development

Journal of Experimental Medicine

Volumn 202, Issue 5, 2005, Pages 617-624

  Li, Shaowei ^a   Takeuchi, Fumiko ^a   Wang, Ji An ^a   Fuller, Christopher ^a   Pacheco Rodriguez, Gustavo ^b   Moss, Joel ^b   Darling, Thomas N ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUBERIN;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CARCINOGENESIS; CELL STIMULATION; CONTROLLED STUDY; DISEASE COURSE; EMBRYO; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; HEMANGIOFIBROMA; HUMAN; HUMAN CELL; HYPERACTIVITY; MONOCYTE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SCREENING TEST; SKIN TUMOR; TUBEROUS SCLEROSIS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; CHEMOKINE CCL2; CHEMOTAXIS; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; FIBROMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARACRINE COMMUNICATION; RATS; TUBEROUS SCLEROSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 24344507757     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20042469     Document Type: Article

References (46)

1. Sampson, J.R. 2003. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis. Biochem. Soc. Trans. 31:592-596.
2. Li, Y., M.N. Corradetti, K. Inoki, and K.L. Guan. 2004. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 29:32-38.
3. Webb, D.W., A. Clarke, A. Fryer, and J.P. Osborne. 1996. The cutaneous features of tuberous sclerosis: a population study. Br. J. Dermatol. 135:1-5.
4. Penneys, N.S., K.J. Smith, and A.J. Nemeth. 1991. Factor XIIIa in the hamartomas of tuberous sclerosis. J. Dermatol. Sci. 2:50-54.
5. Nemeth, A.J., and N.S. Penneys. 1989. Factor XIIIa is expressed by fibroblasts in fibrovascular tumors. J. Cutan. Pathol. 16:266-271.
6. Benjamin, D.R. 1996. Cellular composition of the angiofibromas in tuberous sclerosis. Pediatr. Pathol. Lab. Med. 16:893-899.
7. Arbiser, J.L., D. Brat, S. Hunter, J. D'Armiento, E.P. Henske, Z.K. Arbiser, X. Bai, G. Goldberg, C. Cohen, and S.W. Weiss. 2002. Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J. Am. Acad. Dermatol. 46:376-380.
8. Maldonado, M., M. Baybis, D. Newman, D.L. Kolson, W. Chen, G. McKhann II, D.H. Gutmann, and P.B. Crino. 2003. Expression of ICAM-1, TNF-alpha, NFkappaB, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol. Dis. 14:279-290.
9. Liu, M.Y., L. Poellinger, and C.L. Walker. 2003. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res. 63:2675-2680.
10. Nguyen-Vu, P.A., I. Fackler, A. Rust, J.E. DeClue, C.A. Sander, M. Volkenandt, M. Flaig, R.S. Yeung, and R. Wienecke. 2001. Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis. J. Cutan. Pathol. 28:470-475.
11. Brugarolas, J.B., F. Vazquez, A. Reddy, W.R. Sellers, and W.G. Kaelin Jr. 2003. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 4:147-158.
12. El-Hashemite, N., V. Walker, H. Zhang, and D.J. Kwiatkowski. 2003. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 63:5173-5177.
13. Brugarolas, J., and W.G. Kaelin Jr. 2004. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell. 6:7-10.
14. Kato, M., T. Katsumoto, K. Ohno, S. Kato, F. Herz, and K. Takeshita. 1992. Expression of glial fibrillary acidic protein (GFAP) by cultured angiofibroma stroma cells from patients with tuberous sclerosis. Neuropathol. Appl. Neurobiol. 18:559-565.
15. Onodera, K., Y. Ishibashi, M. Sasaki, and G. Kimura. 1989. Abnormal division and gene expression in cultured cells from a patient with tuberous sclerosis. J. Dermatol. 16:263-269.
16. Kuroda, K., and S. Tajima. 2004. HSP47 is a useful marker for skin fibroblasts in formalin-fixed, paraffin-embedded tissue specimens. J. Cutan. Pathol. 31:241-246.
17. Ishibashi, Y., R. Watanabe, and K. Onodera. 1993. Tuberous Sclerosis: Advances in Clinical and Genetic Research. In Dermatology: Progress & Perspectives. W.H.C. Burgdorf, and S.I. Katz, editors. The Parthenon Publishing Group, New York. 764-766.
18. Valencia, J.C., K. Matsui, C. Bondy, J. Zhou, A. Rasmussen, K. Cullen, Z.X. Yu, J. Moss, and V.J. Ferrans. 2001. Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis. J. Investig. Med. 49:421-433.
19. Hodges, A.K., S. Li, J. Maynard, L. Parry, R. Braverman, J.P. Cheadle, J.E. DeClue, and J.R. Sampson. 2001. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum. Mol. Genet. 10:2899-2905.
20. Yamamoto, T., and K. Nishioka. 2003. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J. Invest. Dermatol. 121:510-516.
21. Yamamoto, T. 2003. Potential roles of CCL2/monocyte chemoattractant protein-1 in the pathogenesis of cutaneous sclerosis. Clin. Exp. Rheumatol. 21:369-375.
22. Ohta, M., Y. Kitadai, S. Tanaka, M. Yoshihara, W. Yasui, N. Mukaida, K. Haruma, and K. Chayama. 2003. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int. J. Oncol. 22:773-778.
23. Gordillo, G.M., D. Onat, M. Stockinger, S. Roy, M. Atalay, M. Beck, and C.K. Sen. 2004. A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelioma proliferation. Am. J. Physiol. Cell Physiol. 287:C866-C873.
24. Salcedo, R., M.L. Ponce, H.A. Young, K. Wasserman, J.M. Ward, H.K. Kleinman, J.J. Oppenheim, and W.J. Murphy. 2000. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood. 96:34-40.
25. Yoshida, S., A. Yoshida, H. Matsui, Y. Takada, and T. Ishibashi. 2003. Involvement of macrophage chemotactic protein-1 and interleukin-1beta during inflammatory but not basic fibroblast growth factor-dependent neovascularization in the mouse cornea. Lab. Invest. 83:927-938.
26. Wada, T., K. Furuichi, N. Sakai, Y. Iwata, K. Kitagawa, Y. Ishida, T. Kondo, H. Hashimoto, Y. Ishiwata, N. Mukaida, et al. 2004. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J. Am. Soc. Nephrol. 15:940-948.
27. Inoshima, I., K. Kuwano, N. Hamada, N. Hagimoto, M. Yoshimi, T. Maeyama, A. Takeshita, S. Kitamoto, K. Egashira, and N. Hara. 2004. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 286:L1038-L1044.
28. de la Rosa, G., N. Longo, J.L. Rodriguez-Fernandez, A. Puig-Kroger, A. Pineda, A.L. Corbi, and P. Sanchez-Mateos. 2003. Migration of human blood dendritic cells across endothelial cell monolayers: adhesion molecules and chemokines involved in subset-specific transmigration. J. Leukoc. Biol. 73:639-649.
29. Mantovani, A., T. Schioppa, S.K. Biswas, F. Marchesi, P. Allavena, and A. Sica. 2003. Tumor-associated macrophages and dendritic cells as prototypic type II polarized myeloid populations. Tumori. 89:459-468.
30. Nakamura, K., I.R. Williams, and T.S. Kupper. 1995. Keratinocyte-derived monocyte chemoattractant protein 1 (MCP-1): analysis in a transgenic model demonstrates MCP-1 can recruit dendritic and Langerhans cells to skin. J. Invest. Dermatol. 105:635-643.
31. Niida, Y., A.O. Stemmer-Rachamimov, M. Logrip, D. Tapon, R. Perez, D.J. Kwiatkowski, K. Sims, M. MacCollin, D.N. Louis, and V. Ramesh. 2001. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am. J. Hum. Genet. 69:493-503.
32. Fackler, I., J.E. DeClue, H. Rust, P.A. Vu, H. Kutzner, A. Rutten, S. Kaddu, C.A. Sander, M. Volkenandt, M.W. Johnson, et al. 2003. Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas. J. Cutan. Pathol. 30:174-177.
33. Wataya-Kaneda, M., Y. Kaneda, O. Hino, H. Adachi, Y. Hirayama, K. Seyama, T. Satou, and K. Yoshikawa. 2001. Cells derived from tuberous sclerosis show a prolonged S phase of the cell cycle and increased apoptosis. Arch. Dermatol. Res. 293:460-469.
34. Darling, T.N., J. Wang, F. Takeuchi, T.C. Lei, S. Pack, Z. Zhuang, and J. Moss. 2002. Allelic deletion of the TSC2 gene in tuberous sclerosis skin tumors and cultured stromal cells. J. Invest. Dermatol. 119:215.
35. Takeuchi, F., J. Wang, J. Moss, and T. Darling. 2003. Hyperphosphorylation of p70S6k and ribosomal protein S6 in tuberous sclerosis skin tumors is inhibited by rapamycin. J. Invest. Dermatol. 121:A165.
36. Govindarajan, B., D.J. Brat, M. Csete, W.D. Martin, E. Murad, K. Litani, C. Cohen, F. Cerimele, M. Nunnelley, B. Lefkove, et al. 2005. Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. J. Biol. Chem. 280:5870-5874.
37. Castro, C., J.M. Campistol, D. Sancho, F. Sanchez-Madrid, E. Casals, and V. Andres. 2004. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis. 172:31-38.
38. Oliveira, J.G., P. Xavier, S.M. Sampaio, C. Henriques, I. Tavares, A.A. Mendes, and M. Pestana. 2002. Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantation. Transplantation. 73:915-920.
39. Wasowska, B.A., X.X. Zheng, T.B. Strom, and J.W. Kupieck-Weglinski. 2001. Adjunctive rapamycin and CsA treatment inhibits monocyte/macrophage associated cytokines/chemokines in sensitized cardiac graft recipients. Transplantation. 71:1179-1183.
40. Harrington, L.S., G.M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, H. Rebholz, J. Barnett, N.R. Leslie, S. Cheng, P.R. Shepherd, et al. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213-223.
41. Shah, O.J., Z. Wang, and T. Hunter. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14:1650-1656.
42. Sartipy, P., and D.J. Loskutoff. 2003. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. USA. 100:7265-7270.
43. Kitamoto, S., and K. Egashira. 2003. Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases. Expert. Rev. Cardiovasc. Ther. 1:393-400.
44. Gordillo, G.M., D. Onat, M. Stockinger, S. Roy, M. Atalay, F.M. Beck, and C.K. Sen. 2004. A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelioma proliferation. Am. J. Physiol. Cell Physiol. 287:C866-C873.
45. Roach, E.S., M.R. Gomez, and H. Northrup. 1998. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J. Child Neurol. 13:624-628.
46. Soucek, T., R.S. Yeung, and M. Hengstschlager. 1998. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc. Natl. Acad. Sci. USA. 95:15653-15658.